Anat Kaphan is the new Vice President of Marketing and Product Management at Mazor Robotics Ltd. Kaphan, who brings over 15 years of executive experience, is the first individual in this newly established role. She will work from the company’s headquarters in Israel and will be a member of the company’s executive leadership team.
Anat Kaphan: A New VP at Mazor Robotics
1 min read Premium comments
“She has developed and successfully executed strategic business plans for new products throughout her career and we are looking forward to the contributions she will make to the corporate team, ” commented Mazor’s Chief Executive Officer Ori Hadomi in the July 7, 2015 news release. “Mazor is an innovative company and our objective is to continually deliver product enhancements. Anat will ensure that we are proactively addressing the market’s evolving needs and maintaining a high level of surgeon satisfaction.”
According to the news release, “Kaphan has over 15 years of experience in product development and strategy and has previously held several product, marketing and business development positions in leading medical device companies, such as Philips Medical Systems and Lumenis Ltd. She holds a Bachelor’s degree in Economics and Accounting from Haifa University and Master of Business Administration in International Marketing from Tel-Aviv University.”
Kaphan told OTW, “For starters, I want to get to know our customers better, focusing on their needs and gain some insight to how they are experiencing our technology. This will allow us to define areas where Mazor Robotics can help our customers grow and improve their utilization of the Renaissance system. I will also work closely with my team to provide a robust product and marketing strategy to support our business moving forward.”
“I would like to play a significant role in evolving Mazor’s corporate strategy with a goal of expanding and spreading our Guided Robotic solution to new applications and market segments. Longer term, I’d like to help support the development of new products, grow our business and increase the value for our customers and patients by focusing on efficiencies, accuracies and user experience.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.